Manufacturing and supplying a cell therapy throws up numerous challenges, especially when stem cell-based products need to be transported and supplied to patients in a consistent and controlled manner.
Here are some of the challenges that face manufacturing and physically distributing cell therapies to for the stem cell and regenerative medicine industry:
Â· Technology – autologous vs allogeneic manufacturing costs
Â· Regulation – what will be the regulatory perspectives and priorities in this space?
Â· Finance – ensuring investment is maintained and reimbursement from payers is achieved
Â· Market – having a collaborative and consented supply chain that is close with the patient
To learn more, download last year's presentation from Simon Ellison, Specialist Services Commercial Manager at the NHS Blood and Transport to see what challenges you may face and how to overcome them.
Simon Ellison will once again be part of the senior speaking faculty at the 2012 World Stem Cells & Regenerative Medicine Congress taking place in London on the 21st-23rd May. Why not download the brochure to see who else has already confirmed to attend.
Found this interesting, why not take a look at this blog post about how Advanced Cell Technology have successfully commenced 2 human clinical trials using hESC-derived RPE cells and how clinical phase challenges are being overcome.